Cathepsin D Drives the Formation of Hybrid Insulin Peptides Relevant to the Pathogenesis of Type 1 Diabetes
- PMID: 36041196
- PMCID: PMC9750942
- DOI: 10.2337/db22-0303
Cathepsin D Drives the Formation of Hybrid Insulin Peptides Relevant to the Pathogenesis of Type 1 Diabetes
Abstract
Hybrid insulin peptides (HIPs) form in pancreatic β-cells through the formation of peptide bonds between proinsulin fragments and other peptides. HIPs have been identified in pancreatic islets by mass spectrometry and are targeted by CD4 T cells in patients with type 1 diabetes (T1D) as well as by pathogenic CD4 T-cell clones in nonobese diabetic (NOD) mice. The mechanism of HIP formation is currently poorly understood; however, it is well established that proteases can drive the formation of new peptide bonds in a side reaction during peptide bond hydrolysis. Here, we used a proteomic strategy on enriched insulin granules and identified cathepsin D (CatD) as the primary protease driving the specific formation of HIPs targeted by disease-relevant CD4 T cells in T1D. We also established that NOD islets deficient in cathepsin L (CatL), another protease implicated in the formation of disease-relevant HIPs, contain elevated levels of HIPs, indicating a role for CatL in the proteolytic degradation of HIPs. In summary, our data suggest that CatD may be a therapeutic target in efforts to prevent or slow the autoimmune destruction of β-cells mediated by HIP-reactive CD4 T cells in T1D.
© 2022 by the American Diabetes Association.
Figures




Similar articles
-
Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion.Science. 2016 Feb 12;351(6274):711-4. doi: 10.1126/science.aad2791. Science. 2016. PMID: 26912858 Free PMC article.
-
HIPs and HIP-reactive T cells.Clin Exp Immunol. 2019 Dec;198(3):306-313. doi: 10.1111/cei.13335. Epub 2019 Jun 17. Clin Exp Immunol. 2019. PMID: 31132145 Free PMC article. Review.
-
Identifying New Hybrid Insulin Peptides (HIPs) in Type 1 Diabetes.Front Immunol. 2021 Apr 30;12:667870. doi: 10.3389/fimmu.2021.667870. eCollection 2021. Front Immunol. 2021. PMID: 33995402 Free PMC article. Review.
-
Characterization of Human CD4 T Cells Specific for a C-Peptide/C-Peptide Hybrid Insulin Peptide.Front Immunol. 2021 May 25;12:668680. doi: 10.3389/fimmu.2021.668680. eCollection 2021. Front Immunol. 2021. PMID: 34113344 Free PMC article.
-
Insulin B-chain hybrid peptides are agonists for T cells reactive to insulin B:9-23 in autoimmune diabetes.Front Immunol. 2022 Aug 10;13:926650. doi: 10.3389/fimmu.2022.926650. eCollection 2022. Front Immunol. 2022. PMID: 36032090 Free PMC article.
Cited by
-
Proinsulin C-peptide is a major source of HLA-DQ8 restricted hybrid insulin peptides recognized by human islet-infiltrating CD4+ T cells.PNAS Nexus. 2024 Nov 1;3(11):pgae491. doi: 10.1093/pnasnexus/pgae491. eCollection 2024 Nov. PNAS Nexus. 2024. PMID: 39554513 Free PMC article.
-
Loss of the Golgi-localized v-ATPase subunit does not alter insulin granule formation or pancreatic islet β-cell function.Am J Physiol Endocrinol Metab. 2024 Mar 1;326(3):E245-E257. doi: 10.1152/ajpendo.00342.2023. Epub 2024 Jan 24. Am J Physiol Endocrinol Metab. 2024. PMID: 38265287 Free PMC article.
-
Using mass spectrometry to identify neoantigens in autoimmune diseases: The type 1 diabetes example.Semin Immunol. 2023 Mar;66:101730. doi: 10.1016/j.smim.2023.101730. Epub 2023 Feb 22. Semin Immunol. 2023. PMID: 36827760 Free PMC article. Review.
-
The beta cell-immune cell interface in type 1 diabetes (T1D).Mol Metab. 2023 Dec;78:101809. doi: 10.1016/j.molmet.2023.101809. Epub 2023 Sep 20. Mol Metab. 2023. PMID: 37734713 Free PMC article. Review.
-
The immunology of type 1 diabetes.Nat Rev Immunol. 2024 Jun;24(6):435-451. doi: 10.1038/s41577-023-00985-4. Epub 2024 Feb 2. Nat Rev Immunol. 2024. PMID: 38308004 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials